Dengue vaccine remains 80.5% effective against severe cases after five years

In a phase 3 clinical trial, the tetravalent dengue vaccine, developed by the Butantan Institute in São Paulo, Brazil, was 80.5% effective against severe dengue cases with warning signs over a five-year period. The results of the trial are published in Nature Medicine.